Literature DB >> 8390954

Quantitative hepatitis C virus RNA and liver histology in chronic hepatitis C patients treated with interferon alfa.

G Yamada1, M Takahashi, H Endo, T Doi, R Miyamoto, H Shimomura, K Yamamoto, T Tsuji.   

Abstract

Seventy patients with hepatitis C virus (HCV) infection received alpha interferon at doses ranging from 3 to 10 million units (MU) daily for eight weeks, three times weekly for 12-24 weeks, or daily and three times weekly for 12-24 weeks. The efficacy of interferon was closely related to the initial blood HCV-RNA values in that these were lower in those who responded completely and partially compared with non-responders. Continuous reductions in HCV-RNA and improvements in the histology activity index score were seen in those who responded completely. In contrast, most of the partial and non-responders remained HCV-RNA positive.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8390954      PMCID: PMC1374039          DOI: 10.1136/gut.34.2_suppl.s133

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  2 in total

1.  Antibodies against synthetic oligopeptides deduced from the putative core gene for the diagnosis of hepatitis virus infection.

Authors:  H Okamoto; F Tsuda; A Machida; E Munekata; Y Akahane; Y Sugai; K Mashiko; T Mitsui; T Tanaka; Y Miyakawa
Journal:  Hepatology       Date:  1992-02       Impact factor: 17.425

2.  Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5'-noncoding region.

Authors:  H Okamoto; S Okada; Y Sugiyama; T Tanaka; Y Sugai; Y Akahane; A Machida; S Mishiro; H Yoshizawa; Y Miyakawa
Journal:  Jpn J Exp Med       Date:  1990-08
  2 in total
  2 in total

1.  Hemodynamics in the portal vein evaluated by pulse wave Doppler ultrasonography in patients with chronic hepatitis C treated with interferon.

Authors:  Shigeo Nakanishi; Katsuya Shiraki; Kouji Yamamoto; Mutsumi Koyama; Noboru Kimura; Takeshi Nakano
Journal:  World J Gastroenterol       Date:  2005-01-21       Impact factor: 5.742

2.  An analysis of risk factors for developing Hepatocellular carcinoma in a group of Hepatitis C patients with stage 3 fibrosis following interferon therapy.

Authors:  Sabina Mahmood; Kazumi Togawa; Miwa Kawanaka; Gouichi Niiyama; Gotaro Yamada
Journal:  Cancer Inform       Date:  2008-04-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.